Targeting succinate dehydrogenase with malonate ester prodrugs decreases renal ischemia reperfusion injury

Renal ischemia reperfusion (IR) injury leads to significant patient morbidity and mortality, and its amelioration is an urgent unmet clinical need. Succinate accumulates during ischemia and its oxidation by the mitochondrial enzyme succinate dehydrogenase (SDH) drives the ROS production that underli...

Full description

Bibliographic Details
Main Authors: Timothy E. Beach, Hiran A. Prag, Laura Pala, Angela Logan, Margaret M. Huang, Anja V. Gruszczyk, Jack L. Martin, Krishnaa Mahbubani, Mazin O. Hamed, Sarah A. Hosgood, Michael L. Nicholson, Andrew M. James, Richard C. Hartley, Michael P. Murphy, Kourosh Saeb-Parsy
Format: Article
Language:English
Published: Elsevier 2020-09-01
Series:Redox Biology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2213231720308454
id doaj-038ddcdac34144049d5f8e694c7a30c8
record_format Article
spelling doaj-038ddcdac34144049d5f8e694c7a30c82020-11-25T03:19:16ZengElsevierRedox Biology2213-23172020-09-0136101640Targeting succinate dehydrogenase with malonate ester prodrugs decreases renal ischemia reperfusion injuryTimothy E. Beach0Hiran A. Prag1Laura Pala2Angela Logan3Margaret M. Huang4Anja V. Gruszczyk5Jack L. Martin6Krishnaa Mahbubani7Mazin O. Hamed8Sarah A. Hosgood9Michael L. Nicholson10Andrew M. James11Richard C. Hartley12Michael P. Murphy13Kourosh Saeb-Parsy14Department of Surgery and Cambridge NIHR Biomedical Research Centre, Biomedical Campus, University of Cambridge, Cambridge, CB2 0QQ, UKMRC Mitochondrial Biology Unit, University of Cambridge, Cambridge, CB2 0XY, UKSchool of Chemistry, University of Glasgow, Glasgow, G12 8QQ, UKMRC Mitochondrial Biology Unit, University of Cambridge, Cambridge, CB2 0XY, UKDepartment of Surgery and Cambridge NIHR Biomedical Research Centre, Biomedical Campus, University of Cambridge, Cambridge, CB2 0QQ, UKMRC Mitochondrial Biology Unit, University of Cambridge, Cambridge, CB2 0XY, UKDepartment of Surgery and Cambridge NIHR Biomedical Research Centre, Biomedical Campus, University of Cambridge, Cambridge, CB2 0QQ, UKDepartment of Surgery and Cambridge NIHR Biomedical Research Centre, Biomedical Campus, University of Cambridge, Cambridge, CB2 0QQ, UKDepartment of Surgery and Cambridge NIHR Biomedical Research Centre, Biomedical Campus, University of Cambridge, Cambridge, CB2 0QQ, UKDepartment of Surgery and Cambridge NIHR Biomedical Research Centre, Biomedical Campus, University of Cambridge, Cambridge, CB2 0QQ, UKDepartment of Surgery and Cambridge NIHR Biomedical Research Centre, Biomedical Campus, University of Cambridge, Cambridge, CB2 0QQ, UKMRC Mitochondrial Biology Unit, University of Cambridge, Cambridge, CB2 0XY, UKSchool of Chemistry, University of Glasgow, Glasgow, G12 8QQ, UKMRC Mitochondrial Biology Unit, University of Cambridge, Cambridge, CB2 0XY, UK; Corresponding author.Department of Surgery and Cambridge NIHR Biomedical Research Centre, Biomedical Campus, University of Cambridge, Cambridge, CB2 0QQ, UK; Corresponding author.Renal ischemia reperfusion (IR) injury leads to significant patient morbidity and mortality, and its amelioration is an urgent unmet clinical need. Succinate accumulates during ischemia and its oxidation by the mitochondrial enzyme succinate dehydrogenase (SDH) drives the ROS production that underlies IR injury. Consequently, compounds that inhibit SDH may have therapeutic potential against renal IR injury. Among these, the competitive SDH inhibitor malonate, administered as a cell-permeable malonate ester prodrug, has shown promise in models of cardiac IR injury, but the efficacy of malonate ester prodrugs against renal IR injury have not been investigated. Here we show that succinate accumulates during ischemia in mouse, pig and human models of renal IR injury, and that its rapid oxidation by SDH upon reperfusion drives IR injury. We then show that the malonate ester prodrug, dimethyl malonate (DMM), can ameliorate renal IR injury when administered at reperfusion but not prior to ischemia in the mouse. Finally, we show that another malonate ester prodrug, diacetoxymethyl malonate (MAM), is more potent than DMM because of its faster esterase hydrolysis. Our data show that the mitochondrial mechanisms of renal IR injury are conserved in the mouse, pig and human and that inhibition of SDH by ‘tuned’ malonate ester prodrugs, such as MAM, is a promising therapeutic strategy in the treatment of clinical renal IR injury.http://www.sciencedirect.com/science/article/pii/S2213231720308454Ischemia reperfusion injuryMalonateSuccinateMitochondriaKidneySuccinate dehydrogenase
collection DOAJ
language English
format Article
sources DOAJ
author Timothy E. Beach
Hiran A. Prag
Laura Pala
Angela Logan
Margaret M. Huang
Anja V. Gruszczyk
Jack L. Martin
Krishnaa Mahbubani
Mazin O. Hamed
Sarah A. Hosgood
Michael L. Nicholson
Andrew M. James
Richard C. Hartley
Michael P. Murphy
Kourosh Saeb-Parsy
spellingShingle Timothy E. Beach
Hiran A. Prag
Laura Pala
Angela Logan
Margaret M. Huang
Anja V. Gruszczyk
Jack L. Martin
Krishnaa Mahbubani
Mazin O. Hamed
Sarah A. Hosgood
Michael L. Nicholson
Andrew M. James
Richard C. Hartley
Michael P. Murphy
Kourosh Saeb-Parsy
Targeting succinate dehydrogenase with malonate ester prodrugs decreases renal ischemia reperfusion injury
Redox Biology
Ischemia reperfusion injury
Malonate
Succinate
Mitochondria
Kidney
Succinate dehydrogenase
author_facet Timothy E. Beach
Hiran A. Prag
Laura Pala
Angela Logan
Margaret M. Huang
Anja V. Gruszczyk
Jack L. Martin
Krishnaa Mahbubani
Mazin O. Hamed
Sarah A. Hosgood
Michael L. Nicholson
Andrew M. James
Richard C. Hartley
Michael P. Murphy
Kourosh Saeb-Parsy
author_sort Timothy E. Beach
title Targeting succinate dehydrogenase with malonate ester prodrugs decreases renal ischemia reperfusion injury
title_short Targeting succinate dehydrogenase with malonate ester prodrugs decreases renal ischemia reperfusion injury
title_full Targeting succinate dehydrogenase with malonate ester prodrugs decreases renal ischemia reperfusion injury
title_fullStr Targeting succinate dehydrogenase with malonate ester prodrugs decreases renal ischemia reperfusion injury
title_full_unstemmed Targeting succinate dehydrogenase with malonate ester prodrugs decreases renal ischemia reperfusion injury
title_sort targeting succinate dehydrogenase with malonate ester prodrugs decreases renal ischemia reperfusion injury
publisher Elsevier
series Redox Biology
issn 2213-2317
publishDate 2020-09-01
description Renal ischemia reperfusion (IR) injury leads to significant patient morbidity and mortality, and its amelioration is an urgent unmet clinical need. Succinate accumulates during ischemia and its oxidation by the mitochondrial enzyme succinate dehydrogenase (SDH) drives the ROS production that underlies IR injury. Consequently, compounds that inhibit SDH may have therapeutic potential against renal IR injury. Among these, the competitive SDH inhibitor malonate, administered as a cell-permeable malonate ester prodrug, has shown promise in models of cardiac IR injury, but the efficacy of malonate ester prodrugs against renal IR injury have not been investigated. Here we show that succinate accumulates during ischemia in mouse, pig and human models of renal IR injury, and that its rapid oxidation by SDH upon reperfusion drives IR injury. We then show that the malonate ester prodrug, dimethyl malonate (DMM), can ameliorate renal IR injury when administered at reperfusion but not prior to ischemia in the mouse. Finally, we show that another malonate ester prodrug, diacetoxymethyl malonate (MAM), is more potent than DMM because of its faster esterase hydrolysis. Our data show that the mitochondrial mechanisms of renal IR injury are conserved in the mouse, pig and human and that inhibition of SDH by ‘tuned’ malonate ester prodrugs, such as MAM, is a promising therapeutic strategy in the treatment of clinical renal IR injury.
topic Ischemia reperfusion injury
Malonate
Succinate
Mitochondria
Kidney
Succinate dehydrogenase
url http://www.sciencedirect.com/science/article/pii/S2213231720308454
work_keys_str_mv AT timothyebeach targetingsuccinatedehydrogenasewithmalonateesterprodrugsdecreasesrenalischemiareperfusioninjury
AT hiranaprag targetingsuccinatedehydrogenasewithmalonateesterprodrugsdecreasesrenalischemiareperfusioninjury
AT laurapala targetingsuccinatedehydrogenasewithmalonateesterprodrugsdecreasesrenalischemiareperfusioninjury
AT angelalogan targetingsuccinatedehydrogenasewithmalonateesterprodrugsdecreasesrenalischemiareperfusioninjury
AT margaretmhuang targetingsuccinatedehydrogenasewithmalonateesterprodrugsdecreasesrenalischemiareperfusioninjury
AT anjavgruszczyk targetingsuccinatedehydrogenasewithmalonateesterprodrugsdecreasesrenalischemiareperfusioninjury
AT jacklmartin targetingsuccinatedehydrogenasewithmalonateesterprodrugsdecreasesrenalischemiareperfusioninjury
AT krishnaamahbubani targetingsuccinatedehydrogenasewithmalonateesterprodrugsdecreasesrenalischemiareperfusioninjury
AT mazinohamed targetingsuccinatedehydrogenasewithmalonateesterprodrugsdecreasesrenalischemiareperfusioninjury
AT sarahahosgood targetingsuccinatedehydrogenasewithmalonateesterprodrugsdecreasesrenalischemiareperfusioninjury
AT michaellnicholson targetingsuccinatedehydrogenasewithmalonateesterprodrugsdecreasesrenalischemiareperfusioninjury
AT andrewmjames targetingsuccinatedehydrogenasewithmalonateesterprodrugsdecreasesrenalischemiareperfusioninjury
AT richardchartley targetingsuccinatedehydrogenasewithmalonateesterprodrugsdecreasesrenalischemiareperfusioninjury
AT michaelpmurphy targetingsuccinatedehydrogenasewithmalonateesterprodrugsdecreasesrenalischemiareperfusioninjury
AT kouroshsaebparsy targetingsuccinatedehydrogenasewithmalonateesterprodrugsdecreasesrenalischemiareperfusioninjury
_version_ 1724623557805211648